What included in the Shed Membership
Fatty Liver Disease: Excess fat accumulation in the liver, known as non-alcoholic fatty liver disease (NAFLD), is commonly associated with obesity and metabolic syndrome
It is still under pre-clinical and clinical development and has not been approved for therapeutic use or any treatment plan by any government health authority or drug administration agency
A missing FDA listing does not prove that a product is safe, effective, or made to drug-quality standards
Only 11.2% of participants stopped the trial due to side effects, and the discontinuation rate dropped significantly after week 24, suggesting those who make it through the early phase generally tolerate it well long-term
These help the body to metabolize fat quicker, burn it faster into an energy source, remove toxins from the liver, reduce fat storage areas and increase energy